Medpace Holdings, Inc. with ticker code (MEDP) now have 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $273.00 and $265.00 suggesting an average Analsyt target price of $269.50. Now with the previous closing price of $242.67 this is indicating there is a potential upside of 11.1%. The 50 day moving average now sits at $253.39 and the 200 moving average now moves to $226.06. The company has a market cap of 7.37B. The stock price for the company is currently $240.34 USD
The potential market cap would be $8,189,779,414 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.21, revenue per share of $57.77 and a 14.47% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
